Nanobiomaterials in drug delivery

Nanobiomaterials in Drug Delivery: Applications of Nanobiomaterials

Volumn , Issue , 2016, Pages 1-37

  Rajabi, Mehdi ^a   Srinivasan, Mathangi ^a   Mousa, Shaker A ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Bioconjugation chemistry; Chemotherapy; Drug delivery; Imaging; Multifunctional nanoparticle; Nanomaterials; Nanotechnology; Targeting

Indexed keywords

BIODEGRADATION; CHEMOTHERAPY; CONTROLLED DRUG DELIVERY; DISEASES; DRUG DELIVERY; DRUG INTERACTIONS; IMAGING TECHNIQUES; MEDICAL APPLICATIONS; MOLECULES; NANOPARTICLES; NANOSTRUCTURED MATERIALS; NANOTECHNOLOGY;

BIO-CONJUGATION; BIOMEDICAL APPLICATIONS; CANCER DIAGNOSIS; CHEMICAL LINKAGE; CHEMOTHERAPEUTIC DRUGS; MULTI-FUNCTIONAL NANOPARTICLES; NANOBIOMATERIALS; TARGETING;

TARGETED DRUG DELIVERY;

EID: 84980390236     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-42866-8.00001-0     Document Type: Chapter

References (200)

1. Aderem A., Underhill D.M. Mechanisms of phagocytosis in macrophages. Annu. Rev. Immunol. 1999, 17:593-623.
2. Aggarwal P., Hall J.B., McLeland C.B., Dobrovolskaia M.A., McNeil S.E. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv. Drug Deliv. Rev 2009, doi:10.1016/j.addr.2009.03.009.
3. Ahmad S., Tester R.F., Corbett A., Karkalas J. Dextran and 5-aminosalicylic acid (5-ASA) conjugates: synthesis, characterisation and enzymic hydrolysis. Carbohydr. Res. 2006, 341:2694-2701. doi:10.1016/j.carres.2006.08.015.
4. Alkilany A.M., Murphy C.J. Toxicity and cellular uptake of gold nanoparticles: what we have learned so far?. J. Nanopart. Res. 2010, 12:2313-2333. doi:10.1007/s11051-010-9911-8.
5. Allen T.M., Martin F.J. Advantages of liposomal delivery systems for anthracyclines. Semin. Oncol 2004, doi:10.1053/j.seminoncol.2004.08.001.
6. Angeli E., Buzio R., Firpo G., Magrassi R., Mussi V., Repetto L., et al. Nanotechnology applications in medicine. Tumori 2008, 206-215. doi:10.1111/j.2041-1626.2011.00046.x.
7. Bae K.H., Lee K., Kim C., Park T.G. Surface functionalized hollow manganese oxide nanoparticles for cancer targeted siRNA delivery and magnetic resonance imaging. Biomaterials 2011, 32:176-184. doi:10.1016/j.biomaterials.2010.09.039.
8. Bao G., Mitragotri S., Tong S. Multifunctional nanoparticles for drug delivery and molecular imaging. Annu. Rev. Biomed. Eng. 2013, 15:253-282.
9. Barenholz Y. Liposome application: problems and prospects. Curr. Opin. Colloid Interface Sci. 2001, http://dx.doi.org/10.1016/S1359-0294(00)00090-X.
10. Bates P.J., Laber D.A., Miller D.M., Thomas S.D., Trent J.O. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp. Mol. Pathol 2009, doi:10.1016/j.yexmp.2009.01.004.
11. Bera D., Qian L., Tseng T.K., Holloway P.H. Quantum dots and their multimodal applications: a review. Materials 2010, doi:10.3390/ma3042260.
12. Bertrand N., Wu J., Xu X., Kamaly N., Farokhzad O.C. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Deliv. Rev. 2014, 66:2-25.
13. Bharali D.J., Mousa S.A. Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise. Pharmacol. Ther. 2010, 128:324-335.
14. Biju V., Itoh T., Ishikawa M. Delivering quantum dots to cells: bioconjugated quantum dots for targeted and nonspecific extracellular and intracellular imaging. Chem. Soc. Rev. 2010, 39:3031-3056. doi:10.1039/b926512k.
15. Blanco E., Kessinger C.W., Sumer B.D., Gao J. Multifunctional micellar nanomedicine for cancer therapy. Exp. Biol. Med. (Maywood) 2009, 234:123-131. doi:10.3181/0808-MR-250.
16. Bozzaro S. Cell surface carbohydrates and cell recognition in Dictyostelium. Cell Differ. 1985, 17:67-82. Available from: http://dx.doi.org/10.1016/0045-6039(85)90473-7.
17. Brandley B.K., Schnaar R.L. Cell-surface carbohydrates in cell recognition and response. J. Leukoc. Biol. 1986, 40:97-111.
18. Brigger I., Dubernet C., Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev 2002, Available from: http://dx.doi.org/10.1016/S0169-409X(02)00044-3.
19. Bucior I., Burger M.M. Carbohydrate-carbohydrate interactions in cell recognition. Curr. Opin. Struct. Biol 2004, doi:10.1016/j.sbi.2004.08.006.
20. Byrne J.D., Betancourt T., Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv. Drug Deliv. Rev. 2008, 60:1615-1626.
21. Cai W., Gao T., Hong H., Sun J. Applications of gold nanoparticles in cancer nanotechnology. Nanotechnol. Sci. Appl. 2008, 17-32. doi:10.2147/NSA.S3788.
22. Cheki M., Moslehi M., Assadi M. Marvelous applications of quantum dots. Eur. Rev. Med. Pharmacol. Sci. 2013, 17:1141-1148.
23. 3+ nanocrystals with enhanced near-infrared to near-infrared upconversion photoluminescence. ACS Nano 2010, 4:3163-3168. doi:10.1021/nn100457j.
24. Chen S., Zhao X., Chen J., Chen J., Kuznetsova L., Wong S.S., et al. Mechanism-based tumor-targeting drug delivery system. Validation of efficient vitamin receptor-mediated endocytosis and drug release. Bioconjug. Chem. 2010, 21:979-987. doi:10.1021/bc9005656.
25. Chen G., Yang C., Prasad P.N. Nanophotonics and nanochemistry: controlling the excitation dynamics for frequency up- and down-conversion in lanthanide-doped nanoparticles. Acc. Chem. Res. 2013, 46:1474-1486. doi:10.1021/ar300270y.
26. Chen H., Ahn R., Van den Bossche J., Thompson D.H., O'Halloran T. Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide. Mol. Cancer Ther. 2009, 8:1955-1963. doi:10.1158/1535-7163.MCT-09-0045.
27. Chithrani B.D., Ghazani A.A., Chan W.C.W. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett. 2006, 6:662-668. doi:10.1021/nl052396o.
28. Choi H.S., Liu W., Misra P., Tanaka E., Zimmer J.P., Itty Ipe B., et al. Renal clearance of quantum dots. Nat. Biotechnol. 2002, 25:1165-1170.
29. Corti C.W., Holliday R.J., Thompson D.T. Developing new industrial applications for gold: gold nanotechnology. Gold Bull 2002, doi:10.1007/BF03214852.
30. Coulman S.A., Anstey A., Gateley C., Morrissey A., McLoughlin P., Allender C., et al. Microneedle mediated delivery of nanoparticles into human skin. Int. J. Pharm. 2009, 366:190-200.
31. Couvreur P. Nanoparticles in drug delivery: past, present and future. Adv. Drug Deliv. Rev. 2013, 65:21-23.
32. Danhier F., Ansorena E., Silva J.M., Coco R., Le Breton A., Préat V. PLGA-based nanoparticles: an overview of biomedical applications. J. Control. Release 2012, doi:10.1016/j.jconrel.2012.01.043.
33. Danhier F., Breton A., Le, Préat V. RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. Mol. Pharm. 2012, 9:2961-2973. doi:10.1021/mp3002733.
34. Daniel M.C., Astruc D. Gold nanoparticles: assembly, supramolecular chemistry, quantum-size-related properties, and applications toward biology, catalysis, and nanotechnology. Chem. Rev 2004, doi:10.1021/cr030698+.
35. Das M., Mishra D., Dhak P., Gupta S., Maiti T.K., Basak A., et al. Biofunctionalized, phosphonate-grafted, ultrasmall iron oxide nanoparticles for combined targeted cancer therapy and multimodal imaging. Small 2009, 5:2883-2893. doi:10.1002/smll.200901219.
36. 3 integrin antagonists. J. Med. Chem. 1999, 42:3033-3040. doi:10.1021/jm970832g.
37. Decuzzi P., Lee S., Bhushan B., Ferrari M.A. Theoretical model for the margination of particles within blood vessels. Ann. Biomed. Eng. 2005, 33:179-190.
38. De Jong W.H., Borm P.J. Drug delivery and nanoparticles: applications and hazards. Int. J. Nanomed. 2008, 3:133-149.
39. Desai N., Trieu V., Yao Z., Louie L., Ci S., Yang A., et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin. Cancer Res. 2006, 12:1317-1324. doi:10.1158/1078-0432.CCR-05-1634.
40. Doherty G.J., McMahon H.T. Mechanisms of endocytosis. Annu. Rev. Biochem. 2009, 78:857-902.
41. Dubey I., Pratviel G., Meunier B. Modification of the thiourea linkage of a fluorescein-oligonucleotide conjugate to a guanidinium motif during ammonia deprotection. Bioconjug. Chem. 1998, 9:627-632. doi:10.1021/bc9702213.
42. Elbayoumi T.A., Torchilin V.P. Current trends in liposome research. Methods Mol. Biol. 2010, 605:1-27. doi:10.1007/978-1-60327-360-2_1.
43. Forssen E.A., Tokes Z.A. Improved therapeutic benefits of doxorubicin by entrapment in anionic liposomes. Cancer Res. 1983, 43:546-550.
44. Gabizon A., Shmeeda H., Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin. Pharmacokinet. 2003, 42:419-436. doi:10.2165/00003088-200342050-00002.
45. Gao W., Chan J.M., Farokhzad O.C. pH-responsive nanoparticles for drug delivery. Mol. Pharm 2010, doi:10.1021/mp100253e.
46. Gao X., Cui Y., Levenson R.M., Chung L.W.K., Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat. Biotechnol. 2004, 22:969-976. doi:10.1038/nbt994.
47. Gaspar M.M., Radomska A., Gobbo O.L., Bakowsky U., Radomski M.W., Ehrhardt C. Targeted delivery of transferrin-conjugated liposomes to an orthotopic model of lung cancer in nude rats. J. Aerosol. Med. Pulm. Drug Deliv 2012, doi:10.1089/jamp.2011.0928.
48. Gavasane A.J. Synthetic biodegradable polymers used in controlled drug delivery system: an overview. Clin. Pharmacol. Biopharm. 2014, 3. doi:10.4172/2167-065X.1000121.
49. Gentile P., Chiono V., Carmagnola I., Hatton P.V. An overview of poly(lactic-co-glycolic) acid (PLGA)-based biomaterials for bone tissue engineering. Int. J. Mol. Sci 2014, doi:10.3390/ijms15033640.
50. Gillies E.R., Fréchet J.M.J. pH-responsive copolymer assemblies for controlled release of doxorubicin. Bioconjug. Chem. 2005, 16:361-368. doi:10.1021/bc049851c.
51. Gillies E.R., Jonsson T.B., Fréchet J.M.J. Stimuli-responsive supramolecular assemblies of linear-dendritic copolymers. J. Am. Chem. Soc. 2004, 126:11936-11943. doi:10.1021/ja0463738.
52. Glaus C., Rossin R., Welch M.J., Bao G. In vivo evaluation of Cu-64-labeled magnetic nanoparticles as a dual-modality PET/MR imaging agent. Bioconjug. Chem. 2010, 21:715-722. doi:10.1021/Bc900511j.
53. Gorelik E., Galili U., Raz A. On the role of cell surface carbohydrates and their binding proteins (lectins) in tumor metastasis. Cancer Metastasis Rev 2001, doi:10.1023/A:1015535427597.
54. Gu J., Cheng W.P., Liu J., Lo S.Y., Smith D., Qu X., et al. pH-triggered reversible "stealth" polycationic micelles. Biomacromolecules 2008, 9:255-262. doi:10.1021/bm701084w.
55. Gu Y., Zhong Y., Meng F., Cheng R., Deng C., Zhong Z. Acetal-linked paclitaxel prodrug micellar nanoparticles as a versatile and potent platform for cancer therapy. Biomacromolecules 2013, 14:2772-2780. doi:10.1021/bm400615n.
56. Guillén D., Sánchez S., Rodríguez-Sanoja R. Carbohydrate-binding domains: multiplicity of biological roles. Appl. Microbiol. Biotechnol 2010, doi:10.1007/s00253-009-2331-y.
57. Gupta A.K., Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 2005, doi:10.1016/j.biomaterials.2004.10.012.
58. Hadjipanayis C.G., Machaidze R., Kaluzova M., Wang L., Schuette A.J., Chen H., et al. EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Cancer Res. 2010, 70:6303-6312. doi:10.1158/0008-5472.CAN-10-1022.
59. Hein C.D., Liu X.-M., Wang D. Click chemistry, a powerful tool for pharmaceutical sciences. Pharm. Res. 2008, 25:2216-2230. doi:10.1007/s11095-008-9616-1.
60. Heo D.N., Yang D.H., Moon H.J., Lee J.B., Bae M.S., Lee S.C., et al. Gold nanoparticles surface-functionalized with paclitaxel drug and biotin receptor as theranostic agents for cancer therapy. Biomaterials 2012, 33:856-866. doi:10.1016/j.biomaterials.2011.09.064.
61. Hilgenbrink A.R., Low P.S. Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J. Pharm. Sci 2005, doi:10.1002/jps.20457.
62. Huang H.-C., Barua S., Sharma G., Dey S.K., Rege K. Inorganic nanoparticles for cancer imaging and therapy. J. Control. Release 2011, 155:344-357. doi:10.1016/j.jconrel.2011.06.004.
63. Huang Z., Sengar R.S., Nigam A., Abadjian M.-C., Potter D.M., Grotjahn D.B., et al. A fluorinated dendrimer-based nanotechnology platform: new contrast agents for high field imaging. Invest. Radiol. 2010, 45:641-654.
64. Hubbell J.A. Synthetic biodegradable polymers for tissue engineering and drug delivery. Curr. Opin. Solid State Mater. Sci 1998, Available from: http://dx.doi.org/10.1016/S1359-0286(98)80098-3.
65. Hughes J.D., Blagg J., Price D.A., Bailey S., DeCrescenzo G.A., Devraj R.V., et al. Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg. Med. Chem. Lett. 2008, 18:4872-4875. doi:10.1016/j.bmcl.2008.07.071.
66. Jain R.K., Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 2010, 7:653-664.
67. Jain S., Hirst D.G., O'Sullivan J.M. Gold nanoparticles as novel agents for cancer therapy. Br. J. Radiol. 2012, 85:101-113. doi:10.1259/bjr/59448833.
68. Jinhao G.A.O., Hongwei G.U., Bing X.U. Multifunctional magnetic nanoparticles: design, synthesis, and biomedical applications. Acc. Chem. Res. 2009, 42:1097-1107. doi:10.1021/ar9000026.
69. Jinno J., Kamada N., Miyake M., Yamada K., Mukai T., Odomi M., et al. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J. Control. Release 2006, 111:56-64.
70. Johnston H.J., Semmler-Behnke M., Brown D.M., Kreyling W., Tran L., Stone V. Evaluating the uptake and intracellular fate of polystyrene nanoparticles by primary and hepatocyte cell lines in vitro. Toxicol. Appl. Pharmacol. 2010, 242:66-78.
71. Jones M.N. Carbohydrate-mediated liposomal targeting and drug delivery. Adv. Drug Deliv. Rev 1994, Available from: http://dx.doi.org/10.1016/0169-409X(94)90013-2.
72. Kale A.A., Torchilin V.P. Design, synthesis, and characterization of pH-sensitive PEG-PE conjugates for stimuli-sensitive pharmaceutical nanocarriers: the effect of substitutes at the hydrazone linkage on the pH stability of PEG-PE conjugates. Bioconjug. Chem. 2007, 18:363-370. doi:10.1021/bc060228x.
73. Karmali P.P., Kotamraju V.R., Kastantin M., Black M., Missirlis D., Tirrell M., et al. Targeting of albumin-embedded paclitaxel nanoparticles to tumors. Nanomedicine 2009, 5:73-82. doi:10.1016/j.nano.2008.07.007.
74. Keyes J.D., Hilton R.J., Farrer J., Watt R.K. Ferritin as a photocatalyst and scaffold for gold nanoparticle synthesis. J. Nanopart. Res. 2011, 13:2563-2575. doi:10.1007/s11051-010-0149-2.
75. Kiessling F., Liu Z., Gätjens J. Advanced nanomaterials in multimodal imaging: design, functionalization, and biomedical applications. J. Nanomater. 2010, 2010. doi:10.1155/2010/894303.
76. Kim D., Chung N.K., Allen S., Tendler S.J.B., Park J.W. Ferritin-based new magnetic force microscopic probe detecting 10nm sized magnetic nanoparticles. ACS Nano 2012, 6:241-248. doi:10.1021/nn203464g.
77. Kim D.K., Zhang Y., Voit W., Rao K.V., Muhammed M. Synthesis and characterization of surfactant-coated superparamagnetic monodispersed iron oxide nanoparticles. J. Magn. Magn. Mater. 2001, 225:30-36. Available from: http://dx.doi.org/10.1016/S0304-8853(00)01224-5.
78. Kim G.J., Nie S. Targeted cancer nanotherapy. Mater. Today 2005, Available from: http://dx.doi.org/10.1016/S1369-7021(05)71034-8.
79. Kim J., Park S., Lee J.E., Jin S.M., Lee J.H., Lee I.S., et al. Designed fabrication of multifunctional magnetic gold nanoshells and their application to magnetic resonance imaging and photothermal therapy. Angew. Chem. Int. Ed. 2006, 45:7754-7758. doi:10.1002/anie.200602471.
80. Kim S.E., Ahn K.Y., Park J.S., Kim K.R., Lee K.E., Han S.S., et al. Fluorescent ferritin nanoparticles and application to the aptamer sensor. Anal. Chem. 2011, 83:5834-5843. doi:10.1021/ac200657s.
81. Kolb H.C., Finn M.G., Sharpless K.B. Click chemistry: diverse chemical function from a few good reactions. Angew. Chem. Int. Ed 2001, Available from: http://dx.doi.org/10.1002/1521-3773(20010601)40:11<2004:AID-ANIE2004>3.0.CO;2-5.
82. Koolpe M., Dail M., Pasquale E.B. An ephrin mimetic peptide that selectively targets the EphA2 receptor. J. Biol. Chem. 2002, 277:46974-46979. doi:10.1074/jbc.M208495200.
83. Kuhn D.A., Vanhecke D., Michen B., Blank F., Gehr P., Petri-Fink A., et al. Different endocytotic uptake mechanisms for nanoparticles in epithelial cells and macrophages. Beilstein J. Nanotechnol. 2014, 5:1625-1636.
84. Laakkonen P., Porkka K., Hoffman J.A., Ruoslahti E. A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat. Med. 2002, 8:751-755. doi:10.1038/nm720.
85. Langguth P., Hanafy A., Frenzel D., Grenier P., Nhamias A., Ohlig T., et al. Nanosuspension formulations for low-soluble drugs: pharmacokinetic evaluation using spironolactone as model compound. Drug Dev. Ind. Pharm. 2005, 31:319-329.
86. Lankveld D.P., Rayavarapu R.G., Krystek P., Oomen A.G., Verharen H.W., van Leeuwen T.G., et al. Blood clearance and tissue distribution of PEGylated and non-PEGylated gold nanorods after intravenous administration in rats. Nanomedicine (Lond.) 2011, 6:339-349.
87. Larson D.R., Zipfel W.R., Williams R.M., Clark S.W., Bruchez M.P., Wise F.W., et al. Water-soluble quantum dots for multiphoton fluorescence imaging in vivo. Science 2003, 300:1434-1436. doi:10.1126/science.1083780.
88. Laurent S., Mahmoudi M. Superparamagnetic iron oxide nanoparticles: promises for diagnosis and treatment of cancer. Int. J. Mol. Epidemiol. Genet. 2011, 2:367-390. doi:10.1021/cn100100e.
89. Laurent S., Dutz S., Häfeli U.O., Mahmoudi M. Magnetic fluid hyperthermia: focus on superparamagnetic iron oxide nanoparticles. Adv. Colloid Interface Sci 2011, doi:10.1016/j.cis.2011.04.003.
90. Leamon C.P., Low P.S. Folate-mediated targeting: from diagnostics to drug and gene delivery. Drug Discov. Today 2001, http://dx.doi.org/10.1016/S1359-6446(00)01594-4.
91. Lee J.F., Stovall G.M., Ellington A.D. Aptamer therapeutics advance. Curr. Opin. Chem. Biol 2006, doi:10.1016/j.cbpa.2006.03.015.
92. Lee S.-Y., Cheng J.-X. Clearance of nanoparticles during circulation. Pharm. Sci. Encyclopedia 2013, 9:1-32.
93. Lepenies B., Lee J., Sonkaria S. Targeting C-type lectin receptors with multivalent carbohydrate ligands. Adv. Drug Deliv. Rev. 2013, 65:1271-1281. doi:10.1016/j.addr.2013.05.007.
94. Li J., Ji J., Holmes L.M., Burgin K.E., Barton L.B., Yu X., et al. Fusion protein from RGD peptide and Fc fragment of mouse immunoglobulin G inhibits angiogenesis in tumor. Cancer Gene Ther. 2004, 11:363-370. doi:10.1038/sj.cgt.7700707.
95. Li Y., Lee P.I. A new bioerodible system for sustained local drug delivery based on hydrolytically activated in situ macromolecular association. Int. J. Pharm. 2010, 383:45-52. doi:10.1016/j.ijpharm.2009.09.005.
96. Li Y., Dong H., Wang K., Shi D., Zhang X., Zhuo R. Stimulus-responsive polymeric nanoparticles for biomedical applications. Sci. China Chem. 2010, 53:447-457. doi:10.1007/s11426-010-0101-4.
97. Lian T., Ho R.J.Y. Trends and developments in liposome drug delivery systems. J. Pharm. Sci 2001, doi:10.1002/jps.1023.
98. Lin M.M., Kim H.-H., Kim H., Muhammed M., Kim D.K. Iron oxide-based nanomagnets in nanomedicine: fabrication and applications. Nano Rev 2010, doi:10.3402/nano.v1i0.4883.
99. Lin P.C., Lin S., Wang P.C., Sridhar R. Techniques for physicochemical characterization of nanomaterials. Biotechnol. Adv 2014, doi:10.1016/j.biotechadv.2013.11.006.
100. Longmire M., Choyke P.L., Kobayashi H. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine (Lond.) 2008, 3:703-717.
101. Low P.S., Henne W.A., Doorneweerd D.D. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc. Chem. Res. 2008, 41:120-129. doi:10.1021/ar7000815.
102. Love S.A., Maurer-Jones M.A., Thompson J.W., Lin Y.S., Haynes C.L. Assessing nanoparticle toxicity. Annu. Rev. Anal. Chem. (Palo Alto Calif.) 2012, 5:181-205.
103. Lu Y., Low P.S. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv. Drug Deliv. Rev 2012, doi:10.1016/j.addr.2012.09.020.
104. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 2001, 41:189-207.
105. Maeda H., Nakamura H., Fang J. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv. Drug Deliv. Rev. 2013, 65:71-79.
106. MaHam A., Tang Z., Wu H., Wang J., Lin Y. Protein-based nanomedicine platforms for drug delivery. Small 2009, doi:10.1002/smll.200801602.
107. Maiti S., Park N., Han J.H., Jeon H.M., Lee J.H., Bhuniya S., et al. Gemcitabine-coumarin-biotin conjugates: a target specific theranostic anticancer prodrug. J. Am. Chem. Soc. 2013, 135:4567-4572. doi:10.1021/ja401350x.
108. Mandal B., Bhattacharjee H., Mittal N., Sah H., Balabathula P., Thoma L.A., et al. Core-shell-type lipid-polymer hybrid nanoparticles as a drug delivery platform. Nanomedicine 2013, doi:10.1016/j.nano.2012.11.010.
109. Mano J.F. Stimuli-responsive polymeric systems for biomedical applications. Adv. Eng. Mater 2008, doi:10.1002/adem.200700355.
110. Massoud T.F., Gambhir S.S. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 2003, 17:545-580. doi:10.1101/gad.1047403.
111. Medeiros S.F., Santos A.M., Fessi H., Elaissari A. Stimuli-responsive magnetic particles for biomedical applications. Int. J. Pharm. 2011, 403:139-161. doi:10.1016/j.ijpharm.2010.10.011.
112. Menjoge A.R., Kannan R.M., Tomalia D.A. Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications. Drug Discov. Today 2010, 15:171-185.
113. Merisko-Liversidge E.M., Liversidge G.G. Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol. Pathol. 2008, 36:43-48.
114. Michalet X., Pinaud F.F., Bentolila L.A., Tsay J.M., Doose S., Li J.J., et al. Quantum dots for live cells, in vivo imaging, and diagnostics. Science 2005, 307:538-544. doi:10.1126/science.1104274.
115. Miele E., Spinelli G.P., Tomao F., Tomao S. Albumin-bound formulation of paclitaxel (Abraxane(registered trademark) ABI-007) in the treatment of breast cancer. Int. J. Nanomed. 2009, 4:99-105.
116. Minko T. Drug targeting to the colon with lectins and neoglycoconjugates. Adv. Drug Deliv. Rev. 2004, 56:491-509. doi:10.1016/j.addr.2003.10.017.
117. Miranda L.P., Shao H., Williams J., Chen S.Y., Kong T., Garcia R., et al. A chemical approach to the pharmaceutical optimization of an anti-HIV protein. J. Am. Chem. Soc. 2007, 129:13153-13159. doi:10.1021/ja073982h.
118. Mitra S., Duggineni S., Koolpe M., Zhu X., Huang Z., Pasquale E.B. Structure-activity relationship analysis of peptides targeting the EphA2 receptor. Biochemistry 2010, 49:6687-6695. doi:10.1021/bi1006223.
119. Moghimi S.M., Hunter A.C., Murray J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 2001, 53:283-318.
120. Moghimi S.M., Hunter A.C., Murray J.C. Nanomedicine: current status and future prospects. FASEB J. 2005, 19:311-330. doi:10.1096/fj.04-2747rev.
121. Mongelard F., Bouvet P. AS-1411, a guanosine-rich oligonucleotide aptamer targeting nucleolin for the potential treatment of cancer, including acute myeloid leukemia. Curr. Opin. Mol. Ther. 2010, 12:107-114.
122. Montet X., Funovics M., Montet-Abou K., Weissleder R., Josephson L. Multivalent effects of RGD peptides obtained by nanoparticle display. J. Med. Chem. 2006, 49:6087-6093. doi:10.1021/jm060515m.
123. Moore A., Marecos E., Bogdanov A., Weissleder R. Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticles in a rodent model. Radiology 2000, 214:568-574.
124. Mulder W.J.M., Koole R., Brandwijk R.J., Storm G., Chin P.T.K., Strijkers G.J., et al. Quantum dots with a paramagnetic coating as a bimodal molecular imaging probe. Nano Lett. 2006, 6:1-6. doi:10.1021/nl051935m.
125. Muthu M. Nanoparticles based on PLGA and its co-polymer: an overview. Asian J. Pharm 2009, doi:10.4103/0973-8398.59948.
126. Nair L.S., Laurencin C.T. Polymers as biomaterials for tissue engineering and controlled drug delivery. Adv. Biochem. Eng. Biotechnol 2006, doi:10.1007/b137240.
127. Nair L.S., Laurencin C.T. Biodegradable polymers as biomaterials. Prog. Polym. Sci 2007, doi:10.1016/j.progpolymsci.2007.05.017.
128. Ng E.W.M., Shima D.T., Calias P., Cunningham E.T., Guyer D.R., Adamis A.P. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov. 2006, 5:123-132. doi:10.1038/nrd1955.
129. Nie S. Understanding and overcoming major barriers in cancer nanomedicine. Nanomedicine (Lond.) 2010, 5:523-528.
130. Noyes A.A., Whitney W.R. The rate of solutions of solid substances in their own solutions. J. Am. Chem. Soc. 1897, 19:930-934.
131. 3+ doped fluoride nanophosphors. Nano Lett. 2008, 8:3834-3838. doi:10.1021/nl802223f.
132. Oberdörster G. Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology. J. Intern. Med. 2010, 89-105. doi:10.1111/j.1365-2796.2009.02187.x.
133. Oberdörster G., Oberdörster E., Oberdörster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ. Health Perspect 2005, doi:10.1289/ehp.7339.
134. Oh N., Park J.H. Endocytosis and exocytosis of nanoparticles in mammalian cells. Int. J. Nanomed. 2014, 9(Suppl. 1):51-63.
135. Oishi M., Nagatsugi F., Sasaki S., Nagasaki Y., Kataoka K. Smart polyion complex micelles for targeted intracellular delivery of PEGylated antisense oligonucleotides containing acid-labile linkages. ChemBioChem 2005, 6:718-725. doi:10.1002/cbic.200400334.
136. Pan D., Caruthers S.D., Hu G., Senpan A., Scott M.J., Gaffney P.J., et al. Ligand-directed nanobialys as theranostic agent for drug delivery and manganese-based magnetic resonance imaging of vascular targets. J. Am. Chem. Soc. 2008, 130:9186-9187. doi:10.1021/ja801482d.
137. Panyam J., Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 2003, 55:329-347.
138. Park H., Yang J., Seo S., Kim K., Suh J., Kim D., et al. Multifunctional nanoparticles for photothermally controlled drug delivery and magnetic resonance imaging enhancement. Small 2008, 4:192-196. doi:10.1002/smll.200700807.
139. Parton R.G., Simons K. The multiple faces of caveolae. Nat. Rev. Mol. Cell Biol. 2007, 8:185-194.
140. Pashov A., Canziani G., MacLeod S., Plaxco J., Monzavi-Karbassi B., Kieber-Emmons T. Targeting carbohydrate antigens in HIV vaccine development. Vaccine 2005, 2168-2175. doi:10.1016/j.vaccine.2005.01.045.
141. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2:751-760. doi:10.1038/nnano.2007.387.
142. Podila R., Brown J.M. Toxicity of engineered nanomaterials: a physicochemical perspective. J. Biochem. Mol. Toxicol 2013, doi:10.1002/jbt.21442.
143. Puri A., Loomis K., Smith B., Lee J.-H., Yavlovich A., Heldman E., et al. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit. Rev. Ther. Drug Carrier Syst. 2009, 26:523-580. doi:10.1615/CritRevTherDrugCarrierSyst.v26.i6.10.
144. Qian Z.M., Li H., Sun H., Ho K. Targeted drug delivery via the transferrin receptor-. Pharmacol. Rev. 2002, 54:561-587.
145. Qiao R., Yang C., Gao M. Superparamagnetic iron oxide nanoparticles: from preparations to in vivo MRI applications. J. Mater. Chem 2009, doi:10.1039/b902394a.
146. Rajabi M., Signorelli P., Gorincioi E., Ghidoni R., Santaniello E. Antiproliferative activity of N6-isopentenyladenosine on MCF-7 breast cancer cells: cell cycle analysis and DNA-binding study. DNA Cell Biol. 2010, 29:687-691. doi:10.1089/dna.2010.1073.
147. Rajabi M., Mehrzad J., Gorincioi E., Santaniello E. Antiproliferative activity of N(6)-isopentenyladenosine on HCT-15 colon carcinoma cell line. Nucleic Acid Ther. 2011, 21:355-358. doi:10.1089/nat.2011.0314.
148. Rajabi M., Gorincioi E., Santaniello E. Antiproliferative activity of kinetin riboside on HCT-15 colon cancer cell line. Nucleosides Nucleotides Nucleic Acids 2012, 31:474-481. doi:10.1080/15257770.2012.681825.
149. Rao C.N.R., Biswas K. Characterization of nanomaterials by physical methods. Annu. Rev. Anal. Chem. (Palo Alto Calif.) 2009, 2:435-462. doi:10.1146/annurev-anchem-060908-155236.
150. Raz A., Meromsky L., Lotan R. Differential expression of endogenous lectins on the surface of nontumorigenic, tumorigenic, and metastatic cells. Cancer Res. 1986, 46:3667-3672.
151. Rubinstein D.B., Stortchevoi A., Boosalis M., Ashfaq R., Ghebrehiwet B., Peerschke E.I.B., et al. Receptor for the globular heads of C1q (gC1q-R, p33, hyaluronan-binding protein) is preferentially expressed by adenocarcinoma cells. Int. J. Cancer 2004, 110:741-750. doi:10.1002/ijc.20105.
152. Sahoo S.K., Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov. Today 2003, 8:1112-1120.
153. Santra S., Kaittanis C., Grimm J., Perez J.M. Drug/dye-loaded, multifunctional iron oxide nanoparticles for combined targeted cancer therapy and dual optical/magnetic resonance imaging. Small 2009, 5:1862-1868. doi:10.1002/smll.200900389.
154. Sengupta S., Eavarone D., Capila I., Zhao G., Watson N., Kiziltepe T., et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 2005, 436:568-572. doi:10.1038/nature03794.
155. Shakesheff K., Evora C., Soriano I., Langer R. The adsorption of poly(vinyl alcohol) to biodegradable microparticles studied by X-ray photoelectron spectroscopy (XPS). J. Colloid Interface Sci. 1997, 185:538-547. doi:10.1006/jcis.1996.4637.
156. Sharpe M., Easthope S.E., Keating G.M., Lamb H.M. Polyethylene glycol-liposomal doxorubicin: a review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi's sarcoma. Drugs 2002, 62:2089-2126.
157. Shen Y., Tang H., Radosz M., Van Kirk E., Murdoch W.J. pH-responsive nanoparticles for cancer drug delivery. Methods Mol. Biol. 2008, 437:183-216. doi:10.1007/978-1-59745-210-6_10.
158. Shin J., Shum P., Grey J., Fujiwara S.I., Malhotra G.S., González-Bonet A., et al. Acid-labile mPEG-vinyl ether-1,2-dioleylglycerol lipids with tunable pH sensitivity: synthesis and structural effects on hydrolysis rates, DOPE liposome release performance, and pharmacokinetics. Mol. Pharm. 2012, 9:3266-3276. doi:10.1021/mp300326z.
159. Shu Y., Pi F., Sharma A., Rajabi M., Haque F., Shu D., et al. Stable RNA nanoparticles as potential new generation drugs for cancer therapy. Adv. Drug Deliv. Rev. 2014, 66:74-89. doi:10.1016/j.addr.2013.11.006.
160. Sinha R., Kim G.J., Nie S., Shin D.M. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol. Cancer Ther. 2006, 5:1909-1917. doi:10.1158/1535-7163.MCT-06-0141.
161. Smart J.D. Lectin-mediated drug delivery in the oral cavity. Adv. Drug Deliv. Rev 2004, doi:10.1016/j.addr.2003.10.016.
162. Sohma Y., Kent S.B.H. Biomimetic synthesis of lispro insulin via a chemically synthesized "mini-proinsulin" prepared by oxime-forming ligation. J. Am. Chem. Soc. 2009, 131:16313-16318. doi:10.1021/ja9052398.
163. Song G., Petschauer J.S., Madden A.J., Zamboni W.C. Nanoparticles and the mononuclear phagocyte system: pharmacokinetics and applications for inflammatory diseases. Curr. Rheumatol. Rev. 2014, 10:22-34.
164. Soppimath K.S., Aminabhavi T.M., Kulkarni A.R., Rudzinski W.E. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release 2001, 70:1-20. Available from: http://dx.doi.org/10.1016/S0168-3659(00)00339-4.
165. Srinivasan M., Rajabi M., Mousa S.A. Multifunctional nanomaterials and their applications in drug delivery and cancer therapy. Nanomaterials 2015, 5(4):1690-1703. doi:10.3390/nano5041690.
166. Straubinger R.M., Lopez N.G., Debs R.J., Hong K., Papahadjopoulos D. Liposome-based therapy of human ovarian cancer: parameters determining potency of negatively charged and antibody-targeted liposomes. Cancer Res. 1988, 48:5237-5245.
167. Suzuki R., Takizawa T., Kuwata Y., Mutoh M., Ishiguro N., Utoguchi N., et al. Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome. Int. J. Pharm. 2008, 346:143-150. doi:10.1016/j.ijpharm.2007.06.010.
168. Taheri A., Dinarvand R., Nouri F.S., Khorramizadeh M.R., Borougeni A.T., Mansoori P., et al. Use of biotin targeted methotrexate-human serum albumin conjugated nanoparticles to enhance methotrexate antitumor efficacy. Int. J. Nanomed. 2011, 6:1863-1874. doi:10.2147/IJN.S23949.
169. Tian H., Tang Z., Zhuang X., Chen X., Jing X. Biodegradable synthetic polymers: preparation, functionalization and biomedical application. Prog. Polym. Sci. 2012, 37:237-280. doi:10.1016/j.progpolymsci.2011.06.004.
170. Toffoli G., Cernigoi C., Russo A., Gallo A., Bagnoli M., Boiocchi M. Overexpression of folate binding protein in ovarian cancers. Int. J. Cancer 1997, 74:193-198. Available from: http://dx.doi.org/10.1002/(SICI)1097-0215(19970422)74:2<193:AID-IJC10>3.0.CO;2-F.
171. Tong R., Cheng J. Ring-opening polymerization-mediated controlled formulation of polylactide-drug nanoparticles. J. Am. Chem. Soc. 2009, 131:4744-4754. doi:10.1021/ja8084675.
172. Torchilin V.P. Micellar nanocarriers: pharmaceutical perspectives. Pharm. Res 2007, doi:10.1007/s11095-006-9132-0.
173. Treat J., Greenspan A., Forst D., Sanchez J.A., Ferrans V.J., Potkul L.A., et al. Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study. J. Natl. Cancer Inst. 1990, 82:1706-1710.
174. Treuel L., Jiang X., Nienhaus G.U. New views on cellular uptake and trafficking of manufactured nanoparticles. J. R. Soc. Interface. 2013, 10:20120939. doi:10.1098/rsif.2012.0939.
175. Tuerk C., Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249:505-510. doi:10.1126/science.2200121.
176. Uchida M., Flenniken M.L., Allen M., Willits D.A., Crowley B.E., Brumfield S., et al. Targeting of cancer cells with ferrimagnetic ferritin cage nanoparticles. J. Am. Chem. Soc. 2006, 128:16626-16633. doi:10.1021/ja0655690.
177. Von Maltzahn G., Ren Y., Park J.-H., Min D.-H., Kotamraju V.R., Jayakumar J., et al. In vivo tumor cell targeting with "click" nanoparticles. Bioconjug. Chem. 2008, 19:1570-1578. doi:10.1021/bc800077y.
178. Walling M.A., Novak J.A., Shepard J.R.E. Quantum dots for live cell and in vivo imaging. Int. J. Mol. Sci 2009, doi:10.3390/ijms10020441.
179. 4 nanoparticles. J. Am. Chem. Soc. 2008, 130:14436-14437. doi:10.1021/ja806519m.
180. Wang J., Byrne J.D., Napier M.E., DeSimone J.M. More effective nanomedicines through particle design. Small 2011, 7:1919-1931.
181. Wang T., D'Souza G.G.M., Bedi D., Fagbohun O.A., Potturi L.P., Papahadjopoulos-Sternberg B., et al. Enhanced binding and killing of target tumor cells by drug-loaded liposomes modified with tumor-specific phage fusion coat protein. Nanomedicine (Lond.) 2010, 5:563-574. doi:10.2217/nnm.10.30.
182. Wang T., Petrenko V.A., Torchilin V.P. Paclitaxel-loaded polymeric micelles modified with MCF-7 cell-specific phage protein: enhanced binding to target cancer cells and increased cytotoxicity. Mol. Pharm. 2010, 7:1007-1014. doi:10.1021/mp1001125.
183. Wang X., Guo Z. Targeting and delivery of platinum-based anticancer drugs. Chem. Soc. Rev 2013, doi:10.1039/c2cs35259a.
184. Wang Y.X., Hussain S.M., Krestin G.P. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur. Radiol. 2001, 11:2319-2331. doi:10.1007/s003300100908.
185. Weinstein J.S., Varallyay C.G., Dosa E., Gahramanov S., Hamilton B., Rooney W.D., et al. Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. J. Cereb. Blood Flow Metab. 2010, 30:15-35. doi:10.1038/jcbfm.2009.192.
186. Wilson D.S., Szostak J.W. In vitro selection of functional nucleic acids. Annu. Rev. Biochem. 1999, 68:611-647. doi:10.1146/annurev.biochem.68.1.611.
187. Wu Y., Loper A., Landis E., Hettrick L., Novak L., Lynn K., et al. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int. J. Pharm. 2004, 285:135-146.
188. Wykosky J., Debinski W. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol. Cancer Res. 2008, 6:1795-1806. doi:10.1158/1541-7786.MCR-08-0244.
189. Xing Y., Rao J. Quantum dot bioconjugates for in vitro diagnostics & in vivo imaging. Cancer Biomark. 2008, 4:307-319.
190. Xu Z., Gu W., Chen L., Gao Y., Zhang Z., Li Y. A smart nanoassembly consisting of acid-labile vinyl ether PEG-DOPE and protamine for gene delivery: preparation and in vitro transfection. Biomacromolecules 2008, 9:3119-3126. doi:10.1021/bm800706f.
191. Yamazaki N., Kojima S., Bovin N.V., André S., Gabius S., Gabius H.J. Endogenous lectins as targets for drug delivery. Adv. Drug Deliv. Rev 2000, Available from: http://dx.doi.org/10.1016/S0169-409X(00)00071-5.
192. Yang W., Cheng Y., Xu T., Wang X., Wen L.P. Targeting cancer cells with biotin-dendrimer conjugates. Eur. J. Med. Chem. 2009, 44:862-868. doi:10.1016/j.ejmech.2008.04.021.
193. Yao X.L., Yoshioka Y., Ruan G.X., Chen Y.Z., Mizuguchi H., Mukai Y., et al. Optimization and internalization mechanisms of PEGylated adenovirus vector with targeting peptide for cancer gene therapy. Biomacromolecules 2012, 13:2402-2409. doi:10.1021/bm300665u.
194. Yeung T., Gilbert G.E., Shi J., Silvius J., Kapus A., Grinstein S. Membrane phosphatidylserine regulates surface charge and protein localization. Science 2008, 319:210-213.
195. Yhee J.Y., Lee S.J., Lee S., Song S., Min H.S., Kang S.W., et al. Tumor-targeting transferrin nanoparticles for systemic polymerized siRNA delivery in tumor-bearing mice. Bioconjug. Chem. 2013, 24:1850-1860. doi:10.1021/bc400226b.
196. Yong K.T., Qian J., Roy I., Lee H.H., Bergey E.J., Tramposch K.M., et al. Quantum rod bioconjugates as targeted probes for confocal and two-photon fluorescence imaging of cancer cells. Nano Lett. 2007, 7:761-765. doi:10.1021/nl063031m.
197. Yu W.W., Chang E., Drezek R., Colvin V.L. Water-soluble quantum dots for biomedical applications. Biochem. Biophys. Res. Commun 2006, doi:10.1016/j.bbrc.2006.07.160.
198. Yu X., Zhang Y., Chen C., Yao Q., Li M. Targeted drug delivery in pancreatic cancer. Biochim. Biophys. Acta. 2010, 1805:97-104. doi:10.1016/j.bbcan.2009.10.001.
199. Zha L., Banik B., Alexis F. Stimulus responsive nanogels for drug delivery. Soft Matter 2011, doi:10.1039/c0sm01307b.
200. 3+-doped NaYbF4 upconversion nanoparticles for in vitro and deeper in vivo bioimaging without overheating irradiation. ACS Nano 2011, 5:3744-3757. doi:10.1021/nn200110j.